[A22-116] Elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide (HIV infection, 2 to < 6 years) – Benefit assessment according to §35a Social Code Book V
Last updated 01.02.2023
Project no.:
A22-116
Commission:
Commission awarded on 01.11.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Indication:
Children aged ≥ 2 to < 6 years and with a body weight of ≥ 14 kg with HIV-1 infection
Result of dossier assessment:
- Treatment-naive children: added benefit not proven
- Pretreated children: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A18-01 | Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (HIV-infected children) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A15-61 | Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide - Benefit assessment according to §35a Social Code Book V | Commission completed |